In the IMpower133, CASPIAN, and CAPSTONE-1 studies, ES-SCLC patients receiving first-line treatment with anti-PD-L1 agents (atezolizumab/durvalumab/adebrelimab) plus standard chemotherapy followed by maintenance anti-PD-L1 agent had significantly better OS than patients receiving chemotherapy alone [9–12]. Here, CD274 is linked to small cell lung carcinoma.